A Phase 1, Single-Dose, Non-Randomized, Open Label Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of DZD9008
Latest Information Update: 23 Dec 2024
Price :
$35 *
At a glance
- Drugs Sunvozertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Dizal Pharmaceutical
- 18 Dec 2024 Status changed from recruiting to completed.
- 29 Feb 2024 Planned End Date changed from 1 Feb 2024 to 1 May 2024.
- 29 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 May 2024.